Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Nebbioso

Showing results (11-20 of 144) with videos related to

Pageof 15
Sort By:
Marine Drugs|January 5, 2021
Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer TherapyMariarosaria Conte, Elisabetta Fontana, Angela Nebbioso, et al.
Epigenetics|October 22, 2016
Identification and characterization of PKF118-310 as a KDM4A inhibitorGianluigi Franci, Federica Sarno, Angela Nebbioso, et al.
Plos Genetics|June 8, 2018
Cancer epigenetics: Moving forwardAngela Nebbioso, Francesco Paolo Tambaro, Carmela Dell'Aversana, et al.
Expert Opinion on Therapeutic Targets|June 2, 2015
Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemiaAngela Nebbioso, Rosaria Benedetti, Mariarosaria Conte, et al.
International Journal of Molecular Sciences|April 3, 2021
Gene Transactivation and Transrepression in MYC-Driven CancersMarika Scafuro, Lucia Capasso, Vincenzo Carafa, et al.
The International Journal of Biochemistry & Cell Biology|June 21, 2005
Acute myeloid leukemia: therapeutic impact of epigenetic drugsLucia Altucci, Nicole Clarke, Angela Nebbioso, et al.
Frontiers in Oncology|November 15, 2021
KDM4 Involvement in Breast Cancer and Possible Therapeutic ApproachesBenluvankar Varghese, Nunzio Del Gaudio, Gilda Cobellis, et al.
The International Journal of Biochemistry & Cell Biology|July 12, 2008
Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemiaAnna Rita Migliaccio, Dante Rotili, Angela Nebbioso, et al.
Nutrients|August 10, 2024
Therapeutic Potential of Natural Compounds Acting through Epigenetic Mechanisms in Cardiovascular Diseases: Current Findings and Future DirectionsPaola Bontempo, Lucia Capasso, Luigi De Masi, et al.
Biochimica Et Biophysica Acta|August 12, 2008
HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2Annamaria Scognamiglio, Angela Nebbioso, Fabio Manzo, et al.
Pageof 15

Showing results (11-20 of 144) with videos related to

Sort By:
Pageof 15
Marine Drugs|January 5, 2021
Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer TherapyMariarosaria Conte, Elisabetta Fontana, Angela Nebbioso, et al.
Epigenetics|October 22, 2016
Identification and characterization of PKF118-310 as a KDM4A inhibitorGianluigi Franci, Federica Sarno, Angela Nebbioso, et al.
Plos Genetics|June 8, 2018
Cancer epigenetics: Moving forwardAngela Nebbioso, Francesco Paolo Tambaro, Carmela Dell'Aversana, et al.
Expert Opinion on Therapeutic Targets|June 2, 2015
Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemiaAngela Nebbioso, Rosaria Benedetti, Mariarosaria Conte, et al.
International Journal of Molecular Sciences|April 3, 2021
Gene Transactivation and Transrepression in MYC-Driven CancersMarika Scafuro, Lucia Capasso, Vincenzo Carafa, et al.
The International Journal of Biochemistry & Cell Biology|June 21, 2005
Acute myeloid leukemia: therapeutic impact of epigenetic drugsLucia Altucci, Nicole Clarke, Angela Nebbioso, et al.
Frontiers in Oncology|November 15, 2021
KDM4 Involvement in Breast Cancer and Possible Therapeutic ApproachesBenluvankar Varghese, Nunzio Del Gaudio, Gilda Cobellis, et al.
The International Journal of Biochemistry & Cell Biology|July 12, 2008
Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemiaAnna Rita Migliaccio, Dante Rotili, Angela Nebbioso, et al.
Nutrients|August 10, 2024
Therapeutic Potential of Natural Compounds Acting through Epigenetic Mechanisms in Cardiovascular Diseases: Current Findings and Future DirectionsPaola Bontempo, Lucia Capasso, Luigi De Masi, et al.
Biochimica Et Biophysica Acta|August 12, 2008
HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2Annamaria Scognamiglio, Angela Nebbioso, Fabio Manzo, et al.
Pageof 15